Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Mathieu Laversanne, Hyuna Sung et al. · CA A Cancer Journal for Clinicians · 2024 · 23.1K citations · Full text

Medicine, Oncology, Cancer Control +16

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman et al. · Clinical Cancer Research · 2013 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · Proceedings of the National Academy of Sciences · 2008 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +14

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan et al. · Journal of Thoracic Oncology · 2015 · 686 citations · Full text

Medicine, Immunology, Oncology +17

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Koichi Azuma, Keiichi Ota, Akihiko Kawahara et al. · Annals of Oncology · 2014 · 677 citations · Full text

Medicine, Molecular Genetics, Oncology +14